Thyrotropin Alfa Administration for High-Dose Activity Radioactive Iodine Treatment in Differentiated Thyroid Cancer – Institutional Practice and Real- World Experience

Authors

  • Ahmad Zaid Zanial Nuclear Medicine Specialist Physician, Nuclear Medicine Department, Hospital Kuala Lumpur, Malaysia
  • Siti Zarina Amir Hassan Nuclear Medicine Specialist Physician, Nuclear Medicine Department, Hospital Kuala Lumpur, Malaysia

DOI:

https://doi.org/10.31344/ijhhs.v9i10.807

Keywords:

differentiated thyroid cancer, thyrotropin alfa

Abstract

Objectives: Radioactive iodine (RAI) treatment after surgery in differentiated thyroid cancer (DTC) is well advocated. Thyrotropin alfa is primarily used in preparing non-metastatic patients for RAI remnant ablation and diagnostic whole-body scan (WBS) or testing of stimulated thyroglobulin (Tg) by elevating the level of thyroid stimulating hormone (TSH). However, only limited data available on its adjunctive use in advanced DTC. We aimed to evaluate institutional real-world practice of thyrotropin alfa among DTC patients receiving high-dose RAI treatment. Methods: Review and analysis of those who received thyrotropin alfa for high-dose RAI >80 mCi at our institution (2017-2018) and attended subsequent clinic monitoring sessions. Positive anti-Tg cases and those defaulted management or follow-up were excluded. In total, 21 patients were included. Safety profile of thyrotropin alfa and clinical parameters including TSH levels, Tg levels at 6-12 months post-treatment and disease status with a minimum follow-up of 3 years. Results: Mean age was 52.6 years old. Majority being females (n=14), follicular thyroid cancer (n=11), stage IV disease (n=12) and without comorbidity (n=11). Main indication for thyrotropin alfa was adjunctive use (n=14). No major side effects reported. All had adequate TSH increment. Pre-treatment serum Tg were markedly raised in 10 cases. Majority had positive immediate post-treatment WBS (n=20). Patients were planned for further RAI treatment (n=14) and oncology referral (n=7). Stage IV patients had higher mean Tg level at 6-12 months after high-dose RAI with thyrotropin alfa compared to Stage I-III patients (269.1 vs. 6.2 ng/ml, p<0.05). Significant association noted between stage IV and substantial residual or RAI refractory disease at follow up (p<0.05). Conclusion: Among our advanced DTC cohort, thyrotropin alfa was generally well-tolerated with no major side effect. Its primary indication was adjunctive use. Stage IV patients had higher mean of post-treatment Tg and substantial residual or RAI refractory disease on follow-up.

International Journal of Human and Health Sciences Supplementary Issue 01: 2025 Page: S38

Downloads

Published

2025-03-30

How to Cite

Zanial, A. Z., & Amir Hassan, S. Z. (2025). Thyrotropin Alfa Administration for High-Dose Activity Radioactive Iodine Treatment in Differentiated Thyroid Cancer – Institutional Practice and Real- World Experience. International Journal of Human and Health Sciences (IJHHS), 9(10), S38. https://doi.org/10.31344/ijhhs.v9i10.807

Issue

Supplementary Issue-1: 2025

Section

E-Poster Presentation

License

Copyright (c) 2025 Ahmad Zaid Zanial, Siti Zarina Amir Hassan

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish in the International Journal of Human and Health Sciences agree to the following terms that:

  1. Authors retain copyright and grant International Journal of Human and Health Sciences the right of first publication of the work.

  2. Creative Commons Licence
    Articles in International Journal of Human and Health Sciences are licensed under a Creative Commons Attribution 4.0 International License CC BY-4.0.This license permits use, distribution and reproduction in any medium, provided the original work is properly cited.
  3. Authors are able to enter into separate, additional contractual arrangements for the distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  4. Authors are permitted to post their work online (e.g., in institutional repositories or on their website) as it can lead to productive exchanges, as well as greater citation of published work.